Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial

Diana Alexandra Echeverria Proano,Fengcai Zhu,Xiaodong Sun,Jesús Zoco,Jyoti Soni,Neeraj Parmar,S. Omar Ali,Huang Zhuoying,Guo Xiang,Li Zhi,Jiang Yonggen,Lu Hongmei,Zhu Qi,He Lu,Du Jiaxi,Li Jia,Gao Qiang,Xu Zhenhui,Wang Jing,Cai Enmao,Pang Hong,Chen Jinyan,Jin Pengfei,Liu Sheng,Zhong Shan,Zhu Jiahong,Song Zhizhou,on behalf of Zoster-076 Study Group

DOI: https://doi.org/10.1080/21645515.2024.2351584

2024-06-07

Human Vaccines & Immunotherapeutics

Abstract:Phase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes zoster (HZ) in healthy ≥ 50-year-olds, with a vaccine efficacy (VE) > 90% across age groups. These pivotal trials did not enroll participants from mainland China where RZV is licensed, therefore similar clinical data are missing for this population. In this phase IV observer-blind study (NCT04869982) conducted between 2021 and 2023 in China, immunocompetent and medically stable ≥ 50-year-olds were randomized 1:1 to receive two RZV or placebo doses, 2 months apart. This study assessed the VE (overall, as confirmatory objective, and descriptively by age category [50–69-year-olds/≥ 70-year-olds]), reactogenicity, and safety of RZV in this Chinese population. Of the 6138 enrolled participants, 99.2% completed the study. During a mean follow-up period of 15.2 (±1.1) months, 31 HZ episodes were confirmed (RZV = 0; placebo = 31) for an incidence rate of 0.0 vs 8.2 per 1000 person-years and an overall VE of 100% (89.82–100). The descriptive VE was 100% (85.29–100) for 50–69-year-olds and 100% (60.90–100) for ≥ 70-year-olds. Solicited adverse events (AEs) were more frequent in the RZV vs the placebo group (median duration: 1–3 days for both groups). Pain and fatigue were the most frequent local and general AEs (RZV: 72.1% and 43.4%; placebo: 9.2% and 5.3%). The frequencies of unsolicited AEs, serious AEs, potential immune-mediated diseases, and deaths were similar between both groups. RZV is well tolerated and efficacious in preventing HZ in Chinese ≥ 50-year-olds, consistent with efficacy studies including worldwide populations with similar age and medical characteristics. What is the context? What is new? What is the impact?

immunology,biotechnology & applied microbiology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the efficacy and safety of the recombinant zoster vaccine (RZV) in adults aged 50 and above in China. Specifically, the study aims to:

1. **Evaluate the efficacy of the vaccine**: Calculate the vaccine efficacy (VE) by comparing the effects of the RZV - vaccinated group and the placebo - vaccinated group in preventing herpes zoster (HZ).
2. **Evaluate the reactogenicity and safety of the vaccine**: Record and analyze adverse events (AEs) that occur after vaccination, especially local and systemic reactions, as well as serious adverse events (SAEs), potential immune - mediated diseases (pIMDs) and deaths.

### Research Background
Herpes zoster is a viral disease caused by the reactivation of the varicella - zoster virus (VZV), mainly manifested as a painful rash. As people age, the risk of developing herpes zoster and its complications (such as post - herpetic neuralgia) increases. RZV is a recombinant zoster vaccine containing an adjuvant, which has been extensively studied in many countries and regions and has shown high efficacy and good safety. However, these studies did not include population data from mainland China, so a special clinical trial is required to evaluate the performance of RZV in the Chinese population.

### Research Design
This is a phase IV randomized, placebo - controlled, observer - blinded study conducted in China between 2021 and 2023. A total of 6,138 healthy adults aged 50 and above were recruited in the study and randomly divided into two groups to receive two doses of RZV or placebo, respectively, with an interval of 2 months. The primary endpoint of the study was the incidence of herpes zoster from 30 days after the second dose of vaccination to the end of the study, and the secondary endpoints included the vaccine efficacy, reactogenicity and safety in different age groups (50 - 69 years old and 70 years old and above).

### Main Results
- **Efficacy**: In the main analysis set (mES), no herpes zoster cases were reported in the RZV group, while 31 cases were reported in the placebo group, and the overall vaccine efficacy was 100% (95% CI: 89.82 - 100). In the subgroups of 50 - 69 years old and 70 years old and above, the vaccine efficacy was also 100%.
- **Reactogenicity**: Local and systemic reactions were more common in the RZV group, especially pain and fatigue. These reactions were usually transient and lasted within 1 - 3 days.
- **Safety**: The serious adverse events, potential immune - mediated diseases and mortality rates were similar in the RZV group and the placebo group, and no serious adverse events directly related to the vaccine were found in either group.

### Conclusion
This study shows that RZV is highly effective and well - tolerated in adults aged 50 and above in China, which is consistent with the research results of populations of similar ages and medical characteristics in other parts of the world. This finding supports the wide application of RZV in China and helps to prevent herpes zoster and its related complications.